ARK Genomic Revolution ETF
ARKG
46 hedge funds and large institutions have $33.5M invested in ARK Genomic Revolution ETF in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 8 closing their positions.
240% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 5
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
69% more capital invested
Capital invested by funds: $19.9M → $33.5M (+$13.7M)
15% more funds holding
Funds holding: 40 → 46 (+6)
1.65% less ownership
Funds ownership: 18.12% → 16.47% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.62M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.36M |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$1.26M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$959K |
| 5 |
LPL Financial
San Diego,
California
|
+$799K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FA
FDx Advisors
Chicago,
Illinois
|
-$1.09M |
| 2 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
-$640K |
| 3 |
EFS
Edelman Financial Services
Fairfax,
Virginia
|
-$561K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$306K |
| 5 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
-$263K |
ARKG Hedge Fund Activity: Q2 2018 in Review
46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q2 2018, worth a combined $33.5M — up 69% from $19.9M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ARKG positions and 8 closed out — a net gain of 6 holders — while 17 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.62M. The largest seller was FDx Advisors, exiting entirely with an estimated $1.09M sold.
- 46 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q2 2018, up from 40 in Q1 2018.
- Funds reported $33.5M of ARK Genomic Revolution ETF stock for Q2 2018, up 69% quarter-over-quarter.
- 14 funds opened new ARK Genomic Revolution ETF positions in Q2 2018 and 8 closed out, a net change of +6 holders.
- The largest ARK Genomic Revolution ETF buyer in Q2 2018 was Morgan Stanley, an estimated $3.62M added.
- The largest ARK Genomic Revolution ETF seller in Q2 2018 was FDx Advisors, an estimated $1.09M sold.
Based on aggregated 13F filings for Q2 2018.